Company data sheet · Glucotrack

Glucotrack: from profit to six straight losses.

Industry: Surgical & Medical Instruments & Apparatus
Headquarters: United States
Ticker: GCTK (Nasdaq)
Sources: SEC filings (2010–2026), Stratrix's verified Decision Cases, market data and official economic statistics for the United States
Data as of: October 18, 2026

From profit to six straight losses. Glucotrack earned $0 billion in 2017–2019. Then it lost money every year from 2020 to 2025: $0.1 billion in all.
The cycle hit it too. The losses began in 2020, when the US economy shrank 2.1%. Part of the damage came from outside; the test is whether it recovered when the economy did.
Ahead of almost everyone like it. From 2016 to 2018, its revenue grew 1699900% in US dollars; the median among 220 large manufacturers grew 16%. It outgrew 100% of them.
Still smaller than it was. Revenue reached $0 billion in 2019, 66% below its 2016 peak of $0 billion.
Leaders came and went. Glucotrack filed 36 leadership changes since 2016, more than 87% of large manufacturers (the median is 20). The day after each, its shares moved a median 0.1 points against its sector. The news was rarely news.

Financial results

As reported in its annual filings. Losses in red.

The full data sheet · Data Plan

Market reaction to disclosed decisions: 91 decision filings since 2016, each linked to the SEC, with the share return against its sector and the S&P 500 the next day and the next year (49 with market data).
Economic context: 7 measures for the United States, every year since 2016, from the official sources.
Peer comparison: against 264 companies of its size in its sector.
Financial results: ten years of revenue, operating and net income, and every annual report, linked.
Methods and sources, so each number can be checked and cited.

The full data sheet downloads with the Data Plan. To see exactly what you get first, open the Boeing sample PDF or Excel.